We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.18%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$937M
AUM Growth
+$390M
Cap. Flow
+$279M
Cap. Flow %
29.82%
Top 10 Hldgs %
69.5%
Holding
35
New
9
Increased
14
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$42.5M
2
WVE icon
Wave Life Sciences
WVE
+$33.6M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$28M
4
DBVT
DBV Technologies
DBVT
+$24.1M
5
PTCT icon
PTC Therapeutics
PTCT
+$21.5M

Top Sells

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$10.3M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$7.01M
3
ARDM
Aradigm Corp Common Stock
ARDM
+$6.7M
4
RGLS
Regulus Therapeutics
RGLS
+$558K

Sector Composition

Rank Sector Weight
1 Healthcare 94.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DERM
26
DELISTED
Dermira, Inc.
DERM
$4M 0.43%
+500,000
New +$10.9M
BLPH
27
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$3.86M 0.41%
123,810
– –
BLCM
28
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$2.3M 0.25%
+35,000
New +$2.64M
RIGL icon
29
CALL
Rigel Pharmaceuticals
RIGL
$681M
$1.77M 0.19%
+50,000
New +$2M
ELDN icon
30
Eledon Pharmaceuticals
ELDN
$261M
$1.64M 0.17%
+18,021
New +$1.33M
SNDX icon
31
Syndax Pharmaceuticals
SNDX
$1.69B
$1.42M 0.15%
100,000
– –
RGLS
32
DELISTED
Regulus Therapeutics
RGLS
$1.22M 0.13%
14,148
-4,167
-23% -$558K
ONTXW
33
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$72K 0.01%
241,644
– –
CNCE
34
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
– –
-400,000
Closed -$10.3M
ARDM
35
DELISTED
Aradigm Corp Common Stock
ARDM
– –
-1,000,000
Closed -$6.7M
1
2

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q1 2018 Portfolio in Review

As of Q1 2018, Boxer Capital held 35 positions worth $937M, up 71% from $547M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Boxer Capital deployed $279M of net new capital in Q1 2018, opening 9 new positions and adding to 14 existing holdings. Its largest new stake was Loxo Oncology, Inc: 400,000 shares worth $46.1M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Ionis Pharmaceuticals, an estimated $7.01M trimmed.

  • Boxer Capital's largest Q1 2018 buy was Loxo Oncology, Inc: 400,000 shares worth $46.1M.
  • Boxer Capital added most to Wave Life Sciences in Q1 2018, an estimated $33.6M increase.
  • Boxer Capital's biggest Q1 2018 reduction was Ionis Pharmaceuticals, cutting an estimated $7.01M.
  • Boxer Capital fully exited Concert Pharmaceuticals, Inc. in Q1 2018, selling an estimated $10.3M.
  • Boxer Capital's ten largest holdings make up 69% of its $937M portfolio in Q1 2018.
  • Boxer Capital opened 9 new positions and closed 2 in Q1 2018.
  • Boxer Capital's portfolio value rose 71% quarter-over-quarter to $937M.

Based on Boxer Capital's 13F filing for Q1 2018, filed 15 May 2018.